Navigation Links
Novel Facebook Application Aims to Prevent Cervical Cancer
Date:10/12/2009

Users can share interactive information on HPV anonymously

WASHINGTON, Oct. 12 /PRNewswire-USNewswire/ -- A new Facebook application has been launched to help educate, motivate and mobilize people to prevent the spread of Humanpapilloma Virus (HPV). "Fact Check: HPV" (www.hpvfactcheck.org) allows users to take an interactive, educational quiz about HPV, find additional resources, and commit to take action, while even allowing concerned friends to anonymously share the application with peers.

The application was developed by Partnership for Prevention and the University of Maryland's College of Information Studies with input from the School of Public Health. The project was funded by the Fund to Prevent Cervical Cancer.

"Use of social networking sites has skyrocketed in the last few years, becoming an excellent channel to promote healthy behaviors," said Robert J. Gould PhD, president of Partnership for Prevention. "Fact Check: HPV will harness the power of social media to increase awareness of this common sexually transmitted disease (STD)."

Use of social networking sites has quadrupled over the last four years from 8 percent in 2005 to over 35 percent in 2008. Over 75% of young adults, age 18-24, have a profile page, the vast majority of whom check it at least weekly.

"Young adults trust information recommended by friends, however, friends are often reticent to share information about stigmatized illnesses such as STDs, mental illnesses, or substance abuse. This project tests a novel strategy that spreads sensitive information through friendship networks, while still retaining anonymity." said Derek L. Hansen, PhD, Assistant Professor at University of Maryland's College of Information Studies. "It also helps us learn how the application spreads through the network and identify misperceptions about HPV based on quiz results."

A recent study conducted by the Centers for Disease Control and Prevention (CDC) found that one in four adolescent girls between the ages of 14-19, or 3.2 million teen girls, is infected with at least one of the most common sexually transmitted diseases -- (HPV, Chlamydia, Herpes, and Trichomoniasis). This study sheds new light on a chronic problem among adolescents in the United States -- one that often receives little attention, in part, due to the sensitive nature of the topic.

STDs can result in serious health consequences when left untreated, including cervical cancer and infertility, and cost the U.S. health care system millions of dollars in medical expenses.

Partnership for Prevention is a membership organization of business, nonprofit and government leaders working to make evidence-based disease prevention and health promotion a national priority. More information is available at www.prevent.org .

SOURCE Partnership for Prevention


'/>"/>
SOURCE Partnership for Prevention
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Toronto researchers discover novel circulation in human eye, new glaucoma treatment target
2. Novel Information about Vulnerable Coronary Artery Plaque to be Presented at Transcatheter Cardiovascular Therapeutics (TCT) 2009
3. New Web Site Will Help Pennsylvanians Learn About, Protect Against Novel H1N1 Flu
4. The Uptake of Novel Therapies Will Drive the Obesity Drug Market to Increase More than Six-Fold to Over $3.2 Billion in 2018
5. Amylin Pharmaceuticals and Biocon Limited Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid
6. Labopharm to present data on its novel trazodone formulation at three upcoming international medical meetings
7. Fifteenth US Patent Issued for aTyr Pharma Novel Biotherapeutic
8. Solution to PREVENT Novel H1N1 (Swine Flu) From Closing Down Schools!
9. The Cosmetic Bootcamp LLC Announces Novel Presentations at Its 3rd Annual Marketing and Management Symposium
10. Abbott to Collaborate With Pfizer Inc on Companion Diagnostic Test to Select Patient Candidates for Novel Investigational Non-Small Cell Lung Cancer Therapy
11. Carnegie Mellon Researchers Develop Novel Tool to Rank Death Rates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... , ... Are You Concerned About Mold In Your Home or Workplace? ... Companies in VA, MD and DC, recently completed its application for the new District ... in the district of Columbia is a good thing stated John Taylor, Owner of ...
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen and Sara ... speak at the American Conference Institute’s 21st Drug & Medical Device Litigation Conference ... Sponsor of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device & ...
(Date:12/2/2016)... Los Angeles, CA (PRWEB) , ... December 02, 2016 , ... For over twenty-four years, ... a lien basis to help personal injury victims find high quality medical care. When ... the Los Angeles area. Fast forward to present day and the now ten-page directory ...
(Date:12/2/2016)... ... December 02, 2016 , ... FlexiSpot, ... of its 60-day free trial program for all of the company’s desktop riser ... a truly hassle free experience. , FlexiSpot’s unique desktop risers use an advanced ...
(Date:12/2/2016)... New York, NY (PRWEB) , ... December 02, 2016 , ... ... Through an exclusive interview with Mediaplanet, Dr. Murthy explains how he was inspired to ... “Early on I learned that medicine is about more than making diagnoses and prescribing ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... -- Seno Medical Instruments, Inc., the company pioneering the development ... the process of diagnosing breast cancer, today announced that ... surveillance and clinical follow-up study at the 2016 ... from December 6-10, 2016 at the Henry B. Gonzalez ... . Seno Medical Instruments will present two ...
(Date:12/5/2016)... and TAIPEI, Taiwan , Dec. ... months of treatment ropeginterferon alfa-2b showed non-inferiority to hydroxyurea (HU) ... a significantly better safety and tolerability profile of ropeginterferon alfa-2b ... from PROUD-PV and the ongoing long-term follow-up trial CONTINUATION-PV to ... PharmaEssentia intends to present this data to the FDA ...
(Date:12/4/2016)... 3, 2016 Sickle cell disease (SCD) is ... blood cells that get stuck in veins and block ... failure, and complications leading to death. Each year, approximately ... and most of them lack access to comprehensive care ... long-term therapy for SCD, a pill called hydroxyurea approved ...
Breaking Medicine Technology: